Leyva TC, Calderón CMA, Pérez RA, Pérez PVJC

Language: Spanish
References: 18
Page: 2-13
PDF size: 293.21 Kb.

ABSTRACT

Objective: research aimed at describing the results of the use of thymoglobulin inducing therapy or basiliximab in patients transplanted at the Institute of Nephrology during 2014.
Method: A descriptive study was carried out in a series of cases for evaluation of technology, from January 2014 to May 2015 in the Transplant Service of the Institute of Nephrology. Universe consisted of 51 patients from a living or cadaveric donor. Creatinine levels were taken into account during the first, third and sixth months after transplantation. The default limit of follow-up was until May 31, 2015, which establishes a maximum observation period of 17 months, which was taken as reference in the survival study. With this date the state of last news of the renal graft and the free interval of acute rejection was determined.
Results: patients between 40 and 59 years old (52.9 %) and male patients (70.6 %) predominated. The most commonly used type of induction was the thymoglobulin scheme. At one year, the infection rate was 30%, the graft rejection rate was 20.6 %, the graft survival rate was 84.3 % and the patient survival rate was 96.1 %.
Conclusions: the therapeutic results were good, low rates of infection and acute rejection were found, with adequate graft and patient survival, with comparable results with both types of induction.

REFERENCES

1. Orantes CM, Herrera R, Almaguer M, Brizuela EG, Hernandez CE, Bayarre H, et al. Chronic kidney disease and associates risk factors in the Bajo Lempa región in the Salvador. Nefrolempa study, 2009. MEDICC [internet]. 2011 [citado 15 mayo 2015];13(4):[aprox 6p]. Disponible en: http://www.scielosp.org/scielo.php?pid=S1555-79602011000400006&script=sci_arttext

2. Li L, Chaudhuri A, Chen A. Efficacy and safety of thymoglobulin induction as an alternative approach for steroid-free maintenance immunosuppression in pediatric renal transplantation. Transplantation. 2010;90(12):1516-20.

3. McKeage K, McCormack PL. Basiliximab: a review of its use as induction therapy in renal transplantation. BioDrugs. 2010;24(1):55-76.

4. Chen G, Gu J, Qiu J, Wang C, Fei J, Deng S, et al. Efficacy and safety of Thymoglobulin and Basiliximab in kidney transplant patients at high risk for acute rejection and delayed graft function Exp Clin Transplant. 2013 Aug;11(4):310-4. doi: 10.6002/ect.2012.0103. Epub 2012 Nov 1.

5. Noyola-Villalobos HF, Espinoza-Mercado F, Jiménez-Chavarría E, Loera-Torres MA, Rivera-Navarrete E. Terapia de inducción con basiliximab en trasplante renal. Doce años de experiencia en el Hospital Central Militar. Rv Mex Trasplantes. 2014;3(1):12-6.

6. Hernández-Jiménez JD, Hernández-Navarrete LS, Rodríguez-Fernández A, Jiménez-López LA, Varela-Pérez V, Irigoyen-Castillo A, et al. Experiencia a largo plazo del programa de trasplante renal del Hospital Regional de Veracruz, México. Rev Mex Trasplantes 2012;1(1):15-21.

7. Borroto Díaz G, Guerrero Díaz C. Uso de riñones para trasplante renal provenientes de donantes de 55 o más años. Rev Cubana Med. 2011:50(2):1-10.

8. Umaña González JA, Mora Palma F, Espinach Roel M. Comparación del rechazo agudo durante el primer año del injerto en pacientes trasplantados renales que recibieron Basiliximab o Daclizumab. Hospital Calderón Guardia. Período 2000-2008. UCR–HSJD. 2012; (VI): 18-25.

9. Martínez-Mier G, Ávila-Pardo SF, Soto-Miranda E, Méndez-López MT, Budar-Fernández LF. Efecto de la inducción en la sobrevida del trasplante renal de donante fallecido en Veracruz, México. Rev Mex Trasplantes. 2014;3(1):17-21.

10. Favi E, Gargiulo A, Spagnoletti G, Salerno MP, Silvestrini N, Valente I, et al. Induction with basiliximab plus thymoglobulin is effective and safe in old-for-old renal transplantation: six-month results of a prospective clinical study. Transplant Proc. 2010 May;42(4):1114-7. doi: 10.1016/j.transproceed.2010.03.073.

11. Webster AC, Ruster LP, McGee R et al. Interleukin 2 receptor antagonists for kldney transplant reclpients. Cochrane Database 3yst Rev. 2010;1:CDM3897. doi: 10.1002/14651858. CD003897.pub3

12. Kesiraju S, Paritala P, MaheswaraRao U, Murthy Athmakuri S, Reddy VS, Sahariah S. Anti-thymocyte globulin versus basiliximab induction in renal transplant recipients: Long-term outcome. Saudi J Kidney Dis Transpl. 2014 Jan;25(1):9-15.

13. Gavela Martínez E , Avila Bernabeu AI , Sancho Calabuig A , Beltrán Catalán S , Escudero Quesada V , Pallardó Mateu LM. Use of basiliximab induction in low-immunological risk renal transplant recipients receiving tacrolimus-based immunosuppression. Transplant Proc. 2009 Jul-Aug;41(6):2337-8. doi: 10.1016/j.transproceed.2009.06.063.

14. Goggins WC , Pascual MA , Powelson JA , Magee C , Tolkoff-Rubin N , Farrell ML, et al. A prospective, randomized, clinical trial of intraoperative versus postoperative Thymoglobulin in adult cadaveric renal transplant recipients.. Transplantation. 2003 Sep 15;76(5):798-802.

15. .Vega J, Videla C, Borja H, Goecke h, Martínez F, Betancour P. Causas de muerte en pacientes con un injerto renal. Rev. Méd. Chile [internet] 2012 [citado 15 mayo 2015];140(3):[aprox 10 p]. Disponible en: http://dx.doi.org/10.4067/S0034-98872012000300003

16. Ulrich F, Niedzwiecki S, Pascher A, Srinivasa MA , Reddy VS, Sahariah S. Long term outcome of ATG vs Basiliximab induction. Eur J of Clin Invest. 2011;41:971-8.

17. Bestard O, Campistol JM, Morales JM, Sánchez-Fructuoso A, Cabello M, Cabello V, et al. Avances en la inmunosupresión para el trasplante renal. Nuevas estrategias para preservar la función renal y reducir el riesgo cardiovascular. Nefrologia. 2012;32:374-84.

18. Willoughby LM, Schnitzler MA, Brennan DC, Pinsky BW, Dzebisashvili N, Buchanan PM, et al. Early outcomes of thymoglobulin and basiliximab induction in kidney transplantation: Application of statistical approaches to reduce bias in observational comparisons. Transplantation. 2009 May 27;87(10):1520-29.